ARTH (Arch Therapeutics) Institutional Ownership : 0.00% (As of Apr. 10, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arch Therapeutics's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arch Therapeutics's Insider Ownership is 8.15%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arch Therapeutics's Float Percentage Of Total Shares Outstanding is 97.96%.

Arch Therapeutics Institutional Ownership Historical Data

The historical data trend for Arch Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Institutional Ownership Chart

Arch Therapeutics Historical Data

The historical data trend for Arch Therapeutics can be seen below:

	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	0.04	0.04	0.04	0.04	0.04	0.04	0.04

Arch Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Arch Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

0HHJ:UK

Address

235 Walnut Street, Suite 6, Framingham, MA, USA, 01702

Website

https://www.archtherapeutics.com

Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.

Executives

Terrence W Norchi	director, officer: President & CEO	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams	officer: CFO and Treasurer	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish	director	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen	officer: Vice President, Sales	C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat	director
Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis	officer: CFO & Treasurer
Avtar S Dhillon	director	C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal	director	100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber	officer: Chief Financial Officer	C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter	officer: Chief Operating Officer	C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616